Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam probe for threat sensitivity in anxiety and depression
NCT06004115Phase 4Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lorazepam in major depressive disorder (MDD), anxiety disorders. Started Nov 2023; status: recruiting.
02
Drugs
lorazepam
03
Conditions
major depressive disorder (MDD)anxiety disorders
Beyond the preview
Go deeper on NCT06004115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004115.